Product Datasheet RBBP6 Antibody NBP1-49542V

Total Page：16

File Type：pdf, Size：1020Kb

Product Datasheet RBBP6 Antibody NBP1-49542V Unit Size: 0.1 ml Store at 4C in the dark. www.novusbio.com [email protected] Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP1-49542V Updated 5/30/2013 v.20.1 Page 1 of 2 v.20.1 Updated 5/30/2013 NBP1-49542V RBBP6 Antibody [DyLight 405] Product Information Unit Size 0.1 ml Concentration Please see the vial label for concentration. If unlisted please contact technical services. Storage Store at 4C in the dark. Clonality Polyclonal Preservative No Preservative Conjugate DyLight 405 Purity Immunogen affinity purified Buffer 50mM sodium borate Product Description Host Rabbit Gene ID 5930 Gene Symbol RBBP6 Species Human Species Reactivity Human. Predicted to react with mouse based on 100% sequence homology. Immunogen A synthetic peptide made to an internal portion of the human RBBP6 protein (between residues 20-70) [UniProt Q7Z6E9] Product Application Details Applications Western Blot, Immunoprecipitation Recommended Dilutions Immunoprecipitation 1:10-1:500, Western Blot 1:100-1:2000 Application Notes This RBBP6 antibody is useful for immunoprecipitation. www.novusbio.com [email protected] Novus Biologicals USA Novus Biologicals Canada 8100 Southpark Way, A-8 461 North Service Road West, Unit B37 Littleton, CO 80120 Oakville, ON L6M 2V5 USA Canada Phone: 303.730.1950 Phone: 905.827.6400 Toll Free: 1.888.506.6887 Toll Free: 855.668.8722 Fax: 303.730.1966 Fax: 905.827.6402 [email protected] [email protected] Novus Biologicals Europe General Contact Information 19 Barton Lane www.novusbio.com Abingdon Science Park Technical Support: [email protected] Abingdon, OX14 3NB, United Kingdom Orders: [email protected] Phone: (44) (0) 1235 529449 General: [email protected] Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 [email protected] Products Related to NBP1-49542V NBP2-33376H Blue Marker Antibody (6F4-F6) [HRP] H00005930-Q01-10ug RBBP6 Partial Recombinant Protein H00005930-T01 RBBP6 Overexpression Lysate (Denatured) NB200-103 p53 Antibody (PAb 240) Limitations This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt. For more information on our guarantee, please visit www.novusbio.com/guarantee. www.novusbio.com [email protected].

Copy Link

Recommended publications

Autism Multiplex Family with 16P11.2P12.2 Microduplication Syndrome in Monozygotic Twins and Distal 16P11.2 Deletion in Their Brother
European Journal of Human Genetics (2012) 20, 540–546 & 2012 Macmillan Publishers Limited All rights reserved 1018-4813/12 www.nature.com/ejhg ARTICLE Autism multiplex family with 16p11.2p12.2 microduplication syndrome in monozygotic twins and distal 16p11.2 deletion in their brother Anne-Claude Tabet1,2,3,4, Marion Pilorge2,3,4, Richard Delorme5,6,Fre´de´rique Amsellem5,6, Jean-Marc Pinard7, Marion Leboyer6,8,9, Alain Verloes10, Brigitte Benzacken1,11,12 and Catalina Betancur*,2,3,4 The pericentromeric region of chromosome 16p is rich in segmental duplications that predispose to rearrangements through non-allelic homologous recombination. Several recurrent copy number variations have been described recently in chromosome 16p. 16p11.2 rearrangements (29.5–30.1 Mb) are associated with autism, intellectual disability (ID) and other neurodevelopmental disorders. Another recognizable but less common microdeletion syndrome in 16p11.2p12.2 (21.4 to 28.5–30.1 Mb) has been described in six individuals with ID, whereas apparently reciprocal duplications, studied by standard cytogenetic and ﬂuorescence in situ hybridization techniques, have been reported in three patients with autism spectrum disorders. Here, we report a multiplex family with three boys affected with autism, including two monozygotic twins carrying a de novo 16p11.2p12.2 duplication of 8.95 Mb (21.28–30.23 Mb) characterized by single-nucleotide polymorphism array, encompassing both the 16p11.2 and 16p11.2p12.2 regions. The twins exhibited autism, severe ID, and dysmorphic features, including a triangular face, deep-set eyes, large and prominent nasal bridge, and tall, slender build. The eldest brother presented with autism, mild ID, early-onset obesity and normal craniofacial features, and carried a smaller, overlapping 16p11.2 microdeletion of 847 kb (28.40–29.25 Mb), inherited from his apparently healthy father.
[Show full text]
Chronic Exposure of Humans to High Level Natural Background Radiation Leads to Robust Expression of Protective Stress Response Proteins S
www.nature.com/scientificreports OPEN Chronic exposure of humans to high level natural background radiation leads to robust expression of protective stress response proteins S. Nishad1,2, Pankaj Kumar Chauhan3, R. Sowdhamini3 & Anu Ghosh1,2* Understanding exposures to low doses of ionizing radiation are relevant since most environmental, diagnostic radiology and occupational exposures lie in this region. However, the molecular mechanisms that drive cellular responses at these doses, and the subsequent health outcomes, remain unclear. A local monazite-rich high level natural radiation area (HLNRA) in the state of Kerala on the south-west coast of Indian subcontinent show radiation doses extending from ≤ 1 to ≥ 45 mGy/y and thus, serve as a model resource to understand low dose mechanisms directly on healthy humans. We performed quantitative discovery proteomics based on multiplexed isobaric tags (iTRAQ) coupled with LC–MS/MS on human peripheral blood mononuclear cells from HLNRA individuals. Several proteins involved in diverse biological processes such as DNA repair, RNA processing, chromatin modifcations and cytoskeletal organization showed distinct expression in HLNRA individuals, suggestive of both recovery and adaptation to low dose radiation. In protein–protein interaction (PPI) networks, YWHAZ (14-3-3ζ) emerged as the top-most hub protein that may direct phosphorylation driven pro- survival cellular processes against radiation stress. PPI networks also identifed an integral role for the cytoskeletal protein ACTB, signaling protein PRKACA; and the molecular chaperone HSPA8. The data will allow better integration of radiation biology and epidemiology for risk assessment [Data are available via ProteomeXchange with identifer PXD022380]. Te basic principles of low linear energy transfer (LET) ionizing radiation (IR) induced efects on mammalian systems have been broadly explored and there exists comprehensive knowledge on the health efects of high doses of IR delivered at high dose rates.
[Show full text]
Structural Characterisation of the Interaction Between RBBP6 and The
Structural characterisation of the interaction between RBBP6 and the multifunctional protein YB-1 by Victor Muleya A thesis submitted in partial fulfilment of the requirements of the M.Sc. Degree in Biotechnology at the Department of Biotechnology, Faculty of Science, University of the Western Cape. Supervisor: Dr. David J.R. Pugh October 2010 i Keywords: RBBP6 YB-1 Interaction RING 15N-HSQC NMR Yeast 2-hybrid Co-immunoprecipitation Homodimerisation Ubiquitination i Abstract Structural characterisation of the interaction between RBBP6 and the multifunctional protein YB-1 Victor Muleya M.Sc. (Biotechnology) thesis, Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape. Retinoblastoma binding protein 6 (RBBP6) is a 250 kDa RING finger-containing protein whose function is known to be mediated through interaction with other proteins. RBBP6 plays a role in the regulation of the tumour suppressor protein p53 and is also thought to be involved in mRNA splicing although its role has yet to be characterised. A recent study utilising a yeast 2-hybrid screen identified the cancer-associated protein known as YB-1 as an interacting partner of RBBP6, and showed that RBBP6 ubiquitinates YB-1, leading to its degradation in the proteasome. Human Y-box binding protein 1 (YB-1) is member of the cold-shock domain family of proteins, which regulates a number of growth related genes through both transcriptional and translational mechanisms. YB-1 is a cell-survival factor whose expression is increased in proliferating normal and cancer cells. It also protects cells against p53-mediated apoptosis by repressing the p53- promoter and down-regulating endogenous p53.
[Show full text]
Itraq‑Based Proteomics Analysis of the Therapeutic Effects of Combined Anticancer Bioactive Peptides and Oxaliplatin on Gastric Cancer Cells
ONCOLOGY REPORTS 43: 201-217, 2020 iTRAQ‑based proteomics analysis of the therapeutic effects of combined anticancer bioactive peptides and oxaliplatin on gastric cancer cells YANAN XU1, XIAN LI2 and XIULAN SU1,2 1Department of Cell Biology, College of Basic Medicine, Capital Medical University, Beijing 100069; 2Clinical Medical Research Center, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia Autonomous Region 010050, P.R. China Received April 2, 2019; Accepted September 25, 2019 DOI: 10.3892/or.2019.7406 Abstract. The combination of chemotherapeutic modalities cells treated with ACBP, OXA and ACBP-OXA exhibited 17 may be more effective in treating gastric cancer compared (10 up- and 7 downregulated), 111 (27 up- and 84 downregu- with any modality alone. Previous studies have demonstrated lated) and 128 (53 up- and 75 downregulated) differentially that the combination of anticancer bioactive peptides (ACBP) expressed proteins, respectively. Of the 256 differentially and oxaliplatin (OXA) significantly inhibited the growth of the expressed proteins, 6 (TPX2, NUSAP1, TOP2A, YAP, MKi-67 gastric cancer cell line MKN-45, promoted the apoptosis of and GPC4) were verified by the parallel reaction monitoring MKN-45 cells, and caused an irreversible arrest of the MKN-45 method, which revealed that TPX2, NUSAP1, TOP2A, YAP, cell cycle in the G2/M phase. In the present study, an isobaric MKi-67 and GPC4 expression decreased with ACBP-OXA tag for relative and absolute quantitation (iTRAQ)-based treatment. The cellular localization, functional annotation and quantitative proteomics technique was used to determine the biological pathways of differentially expressed proteins were effect of ACBP-OXA treatment on the proteomics profile examined by Gene Ontology and Kyoto Encyclopedia of Genes of MKN-45 cells.
[Show full text]
Downloaded with Ma- Disease D D
bioRxiv preprint doi: https://doi.org/10.1101/483065; this version posted November 29, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. F1000Research 2016 - DRAFT ARTICLE (PRE-SUBMISSION) Bioinformatics Approach to Identify Diseasome and Co- morbidities Effect of Mitochondrial Dysfunctions on the Progression of Neurological Disorders Md. Shahriare Satu1, Koushik Chandra Howlader2, Tajim Md. Niamat Ullah Akhund3, Fazlul Huq4, Julian M.W. Quinn5, and Mohammad Ali Moni4,5 1Dept. of CSE, Gono Bishwabidyalay, Dhaka, Bangladesh 2Dept. of CSTE, Noakhali Science and Technology University, Noakhali, Bangladesh 3Institute of Information Technology, Jahangirnagar University, Dhaka, Bangladesh 4School of Biomedical Science, Faculty of Medicine and Health, The University of Sydney, Australia 5Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia Abstract Mitochondrial dysfunction can cause various neurological diseases. We therefore developed a quantitative framework to explore how mitochondrial dysfunction may inﬂuence the progression of Alzheimer’s, Parkinson’s, Hunting- ton’s and Lou Gehrig’s diseases and cerebral palsy through analysis of genes showing altered expression in these conditions. We sought insights about the gene proﬁles of mitochondrial and associated neurological diseases by investigating gene-disease networks, KEGG pathways, gene ontologies and protein-protein interaction network. Gene disease networks were constructed to connect shared genes which are commonly found between the neurological diseases and Mito- chondrial Dysfunction. We also generated KEGG pathways and gene ontologies to explore functional enrichment among them, and protein-protein interaction networks to identify the shared protein groups of these diseases.
[Show full text]
Investigation of the Intra-Cellular Localisation of Retinoblastoma Binding Protein 6 Using Immunofluorescence Microscopy
Investigation of the intra-cellular localisation of Retinoblastoma Binding Protein 6 using immunofluorescence microscopy Anna Victoria Szmyd-Potapczuk A thesis submitted in fulfilment of the requirement for the degree of Doctor Philosophiae in the Faculty of Natural Science, University of the Western Cape Supervisor: Prof David JR Pugh September 2017 I ABSTRACT Investigation of the intra-cellular localisation of Retinoblastoma Binding Protein 6 using immunofluorescence microscopy AV Szmyd-Potapczuk PhD thesis, Department of Biotechnology, Faculty of Natural Science, University of the Western Cape Human Retinoblastoma Binding Protein 6 (RBBP6) is a 200 kDa protein that has been implicated in a number of crucial cellular processes. It forms part of the mRNA 3'-end processing complex in both humans and yeast, and it contains an RS-like domain and interacts with core splicing proteins, suggesting multiple roles in mRNA processing. Through its RING finger domain it has been implicated in catalysing ubiquitination of the tumour suppressor p53, the oncogene Y-Box Binding Protein 1 (YB-1) and the DNA replication-associated protein zBTB38. It is one of only a few proteins known to bind to both p53 and pRb. At the N-terminus of the protein is the DWNN domain, an ubiquitin-like domain which is found only in this protein family. Four protein isoforms of RBBP6 have been identified in humans, all of which contain the DWNN domain: isoform 1 contains 1972 residues, isoform 2 contains 1758 residues and isoform 4 contains 952 residues. Isoform 3, which contains the first 101 residues of the full length protein (isoform 1), including the DWNN domain, followed by an unique 17-amino acid tail, is reported to be expressed independently of the other isoforms and to be down-regulated in a number of cancers.
[Show full text]
Mechanisms of Action of Coxiella Burnetii Effectors Inferred from Host-Pathogen Protein Interactions
RESEARCH ARTICLE Mechanisms of action of Coxiella burnetii effectors inferred from host-pathogen protein interactions Anders Wallqvist1, Hao Wang1, Nela Zavaljevski1, Vesna MemisÏević1, Keehwan Kwon2, Rembert Pieper2, Seesandra V. Rajagopala2, Jaques Reifman1* 1 Department of Defense Biotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced Technology Research Center, U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland, United States of America, 2 J. Craig Venter Institute, Rockville, Maryland, United States of America a1111111111 a1111111111 * [email protected] a1111111111 a1111111111 a1111111111 Abstract Coxiella burnetii is an obligate Gram-negative intracellular pathogen and the etiological agent of Q fever. Successful infection requires a functional Type IV secretion system, which OPEN ACCESS translocates more than 100 effector proteins into the host cytosol to establish the infection, Citation: Wallqvist A, Wang H, Zavaljevski N, restructure the intracellular host environment, and create a parasitophorous vacuole where MemisÏević V, Kwon K, Pieper R, et al. (2017) the replicating bacteria reside. We used yeast two-hybrid (Y2H) screening of 33 selected C. Mechanisms of action of Coxiella burnetii effectors burnetii effectors against whole genome human and murine proteome libraries to generate inferred from host-pathogen protein interactions. a map of potential host-pathogen protein-protein interactions (PPIs). We detected 273 PLoS ONE 12(11): e0188071. https://doi.org/ 10.1371/journal.pone.0188071 unique interactions between 20 pathogen and 247 human proteins, and 157 between 17 pathogen and 137 murine proteins. We used orthology to combine the data and create a sin- Editor: Zhao-Qing Luo, Purdue University, UNITED STATES gle host-pathogen interaction network containing 415 unique interactions between 25 C.
[Show full text]
Anti-RBBP6 Antibody (ARG41302)
Product datasheet [email protected] ARG41302 Package: 50 μg anti-RBBP6 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes RBBP6 Tested Reactivity Hu, Ms Tested Application ICC/IF, IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name RBBP6 Antigen Species Human Immunogen Recombinant protein corresponding to aa. 97-351 of Human RBBP6. Conjugation Un-conjugated Alternate Names PACT; Retinoblastoma-binding protein 6; E3 ubiquitin-protein ligase RBBP6; EC 6.3.2.-; SNAMA; Proliferation potential-related protein; RBQ-1; Protein P2P-R; Retinoblastoma-binding Q protein 1; MY038; P2P-R; p53-associated cellular protein of testis Application Instructions Application table Application Dilution ICC/IF 1:100 IHC-P 1:100 WB 2 - 5 µg/ml Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control Mouse brain Calculated Mw 202 kDa Properties Form Liquid Purification Purification with Protein G. Buffer 0.01M PBS (pH 7.4), 0.03% Proclin 300 and 50% Glycerol. Preservative 0.03% Proclin 300 Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/3 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol RBBP6 Gene Full Name retinoblastoma binding protein 6 Background The retinoblastoma tumor suppressor (pRB) protein binds with many other proteins.
[Show full text]
Sample Report for Solid Tumor Profile Plus (Lung Cancer)
175 Technology Drive, Suite 100, Irvine, CA 92618 Tel: 1-866-484-8870 www.genomictestingcooperative.com CLIA #: 05D2111917 CAP #: 9441547 Solid Tumor Profile Plus Patient Name: Ordering Physician: Date of Birth: Accession #: Gender (M/F): F Specimen Type: Tissue Client: Specimen ID: Case #: Body Site: LUNG MRN: Indication for Testing: Collected Date: 06/18/2020 Time: 11:30 AM Received Date: 07/22/2020 Time: 12:17 PM Tumor Type: Reported Date: 08/02/2020 Time: 02:31 PM Test Description: This is a comprehensive molecular profile which uses next generation sequencing (NGS), fragment length analysis and Sanger Sequencing testing to identify molecular abnormalities in DNA of 434 genes and RNA in 1,385 genes with a focus on 55 genes implicated in solid tumors. Whenever possible, clinical relevance and implications of detected abnormalities are described below. Detected Genomic Alterations Detected Genomic Alterations Level 1 Level 2 Level 3 Level 4 Other (FDA-Approved) (Standard of Care) (Clinical Evidence) (Biological Relevance) No evidence of Tumor Mutation PTEN, RB1, ERBB4, CDH1, CBFB, Chromosomal microsatellite Burden-High: 17 KMT2C (2 RBBP6, PBRM1 (5 structural instability Mut/Mb mutations) mutations), GATA1, abnormalities HOXA11, NUP93, including: 1q+, 4q-, RIT1 6p+, 7q+, -13, +15, 17p- and others. -t(5;14)(q35; q32) - -t(3;10)(q26;q23) - - FGFR4-CEP170B PTEN-TBL1XR1 fusion mRNA fusion mRNA Heterogeneity Tumor Heterogeneity There is a dominant abnormal clone with CDH1 mutation. The PTEN, CBFB, RBBP6, RB1, PBRM1 (5 mutations), ERBB4, GATA1, HOXA11, KMT2C, NUP93, KMT2C, and RIT1 mutations are detected in subclones. Page 1 of 10 175 Technology Drive, Suite 100, Irvine, CA 92618 Tel: 1-866-484-8870 www.genomictestingcooperative.com CLIA #: 05D2111917 CAP #: 9441547 Diagnostic Implications Diagnostic Implications CDH1, PTEN, CBFB, These abnormalities are consistent with aggressive neoplasm.
[Show full text]
Downloaded Per Proteome Cohort Via the Web- Site Links of Table 1, Also Providing Information on the Deposited Spectral Datasets
www.nature.com/scientificreports OPEN Assessment of a complete and classifed platelet proteome from genome‑wide transcripts of human platelets and megakaryocytes covering platelet functions Jingnan Huang1,2*, Frauke Swieringa1,2,9, Fiorella A. Solari2,9, Isabella Provenzale1, Luigi Grassi3, Ilaria De Simone1, Constance C. F. M. J. Baaten1,4, Rachel Cavill5, Albert Sickmann2,6,7,9, Mattia Frontini3,8,9 & Johan W. M. Heemskerk1,9* Novel platelet and megakaryocyte transcriptome analysis allows prediction of the full or theoretical proteome of a representative human platelet. Here, we integrated the established platelet proteomes from six cohorts of healthy subjects, encompassing 5.2 k proteins, with two novel genome‑wide transcriptomes (57.8 k mRNAs). For 14.8 k protein‑coding transcripts, we assigned the proteins to 21 UniProt‑based classes, based on their preferential intracellular localization and presumed function. This classifed transcriptome‑proteome profle of platelets revealed: (i) Absence of 37.2 k genome‑ wide transcripts. (ii) High quantitative similarity of platelet and megakaryocyte transcriptomes (R = 0.75) for 14.8 k protein‑coding genes, but not for 3.8 k RNA genes or 1.9 k pseudogenes (R = 0.43–0.54), suggesting redistribution of mRNAs upon platelet shedding from megakaryocytes. (iii) Copy numbers of 3.5 k proteins that were restricted in size by the corresponding transcript levels (iv) Near complete coverage of identifed proteins in the relevant transcriptome (log2fpkm > 0.20) except for plasma‑derived secretory proteins, pointing to adhesion and uptake of such proteins. (v) Underrepresentation in the identifed proteome of nuclear‑related, membrane and signaling proteins, as well proteins with low‑level transcripts.
[Show full text]
Transcriptional Regulators Are Upregulated in the Substantia Nigra
Journal of Emerging Investigators Transcriptional Regulators are Upregulated in the Substantia Nigra of Parkinson’s Disease Patients Marianne Cowherd1 and Inhan Lee2 1Community High School, Ann Arbor, MI 2miRcore, Ann Arbor, MI Summary neurological conditions is an established practice (3). Parkinson’s disease (PD) affects approximately 10 Significant gene expression dysregulation in the SN and million people worldwide with tremors, bradykinesia, in the striatum has been described, particularly decreased apathy, memory loss, and language issues. Though such expression in PD synapses. Protein degradation has symptoms are due to the loss of the substantia nigra (SN) been found to be upregulated (4). Mutations in SNCA brain region, the ultimate causes and complete pathology are unknown. To understand the global gene expression (5), LRRK2 (6), and GBA (6) have also been identified changes in SN, microarray expression data from the SN as familial markers of PD. SNCA encodes alpha- tissue of 9 controls and 16 PD patients were compared, synuclein, a protein found in presynaptic terminals that and significantly upregulated and downregulated may regulate vesicle presence and dopamine release. genes were identified. Among the upregulated genes, Eighteen SNCA mutations have been associated with a network of 33 interacting genes centered around the PD and, although the exact pathogenic mechanism is cAMP-response element binding protein (CREBBP) was not confirmed, mutated alpha-synuclein is the major found. The downstream effects of increased CREBBP- component of protein aggregates, called Lewy bodies, related transcription and the resulting protein levels that are often found in PD brains and may contribute may result in PD symptoms, making CREBBP a potential therapeutic target due to its central role in the interactive to cell death.
[Show full text]
The C. Elegans Homolog of RBBP6 (RBPL-1) Regulates Fertility Through Controlling Cell Proliferation in the Germline and Nutrient Synthesis in the Intestine
The C. elegans Homolog of RBBP6 (RBPL-1) Regulates Fertility through Controlling Cell Proliferation in the Germline and Nutrient Synthesis in the Intestine Ping Huang1,2,XuanMa1, Yanmei Zhao1, Long Miao1* 1 Laboratory of Noncoding RNA, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China, 2 University of Chinese Academy of Sciences, Beijing, China Abstract RBBP6 (retinoblastoma binding protein 6, also known as PACT or P2P-R in humans) is a multi-domain protein that functions in multiple processes, such as mitosis, cell differentiation, and cell apoptosis. RBBP6 is evolutionarily conserved and is present in unicellular organisms to mammals. Studies of RBBP6 have mostly focused on its RB- and p53-binding domains, which are found exclusively in mammals. Here, we investigated the C. elegans homolog of RBBP6 to explore the functional roles of its other domains. We found that RBPL-1, the homolog of RBBP6 in C. elegans, is indispensable for worm development. RNAi silencing of rbpl-1 led to embryonic lethality, as well as defects in oocyte production and intestine development. rbpl-1 RNAi worms showed defects in germ cell proliferation, suggesting that RBPL-1 regulates mitosis. Moreover, RNAi silencing of rbpl-1 inhibited nutrient synthesis in the worm intestine. RBPL-1, as a nucleolus protein, was found to be expressed in diverse tissues and necessary for both germline and soma development. Using microarray analysis, we identified <700 genes whose expression levels were changed at least 10-fold in rbpl-1 worms. We propose that RBPL-1, like its yeast homolog, may regulate gene expression as an mRNA cleavage and polyadenylation factor.
[Show full text]